Trial Profile
An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONODO
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.